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HIV-1-associated dementia (HAD)1 is a severe form of neurological disability, observed in 20 –30% of patients with acquired immunodeficiency syndrome (AIDS) (1). The histopathological signs of HAD include infiltration of inflammatory cells,
astrogliosis, pallor of myelin sheaths, abnormalities of dendritic processes, and neuronal apoptotic death. Productive
HIV-1 infection in the brain occurs predominantly in macrophages, microglia, and multinucleated giant cells (2, 3). Infection of astrocytes may also occur with restricted virus replication, affirming that the effects of HIV on astrocytes may be
indirect (4 – 6). Neurons also are not infected. The correlation
between the disease severity and the viral load is unconvincing,
and the neurotoxicity of the virus itself is controversial (4, 7, 8).
Furthermore, little or no virus has been found in AIDS-related
vacuolar myelopathy (9). Taken together, these findings suggest that indirect mechanisms possibly play an important role
in the observed neuronal loss in HAD.
One means by which indirect effects may be exerted upon
neural cells is via nitric oxide (NO) production. NO, a diffusible
gas, plays an important role in many physiological and diverse
pathophysiological conditions (10, 11). At low concentration,
NO has been shown to play a unique role in neurotransmission
and vasodilation, whereas at higher concentrations it is neurotoxic (10, 11). Consistently, NO, derived in excessive amount
from the activation of inducible nitric-oxide synthase (iNOS) in
glial cells (astroglia and microglia) and macrophages, is assumed to contribute to neuronal abnormalities in HAD (12–14).
By immunocytochemical analysis, Zhao et al. (15) have shown
that iNOS expression is present in all of the HAD cases tested
and that iNOS immunoreactivity is localized primarily to reactive astrocytes. Analysis of cerebrospinal fluid and serum
from HAD patients has shown increased levels of nitrite and
nitrate compared with non-HIV infected patients (16). The
reaction of NO with O2⫺ forms peroxynitrite, ONOO⫺, a strong
nitrosating agent capable of nitrosating tyrosine residues of a
protein to nitrotyrosine. Consistently increasing levels of nitrotyrosine have been found in brains of demented, but not in
nondemented, AIDS patients (17). Subsequently, reverse transcription-PCR and Western blot analysis of normal and HAD
brains also show markedly higher expression of iNOS mRNA
and protein in HAD brains than in normal brains (13).
However, the mechanism by which NO is produced in the
brains of HAD patients is unclear. The HIV-1 regulatory pro-

1
The abbreviations used are: HAD, HIV-1-associated dementia; HIV,
human immunodeficiency virus; iNOS, inducible nitric-oxide synthase;
NMA, L-NG-monomethylarginine; D-NMA, D-NG-monomethylarginine;
ERK, extracellular signal-regulated kinase; MAPK, mitogen-activated
protein kinase; CNS, central nervous system; CAT, chloramphenicol
acetyltransferase; RSV, Rous sarcoma virus; C/EBP, CCAAT enhancerbinding protein; IKK, IB kinase; LIP, liver inhibitory protein.
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Human immunodeficiency virus type 1 (HIV-1) infection is known to cause neuronal injury and dementia in
a significant proportion of patients. However, the mechanism by which HIV-1 mediates its deleterious effects in
the brain is poorly defined. The present study was undertaken to investigate the effect of the HIV-1 tat gene
on the expression of inducible nitric-oxide synthase
(iNOS) in human U373MG astroglial cells and primary
astroglia. Expression of the tat gene as RSV-tat but not
that of the CAT gene as RSV-CAT in U373MG astroglial
cells led to the induction of NO production and the expression of iNOS protein and mRNA. Induction of NO
production by recombinant HIV-1 Tat protein and inhibition of RSV-tat-induced NO production by anti-Tat
antibodies suggest that RSV-tat-induced production of
NO is dependent on Tat and that Tat is secreted from
RSV-tat-transfected astroglia. Similar to U373MG astroglial cells, RSV-tat also induced the production of NO in
human primary astroglia. The induction of human iNOS
promoter-derived luciferase activity by the expression
of RSV-tat suggests that RSV-tat induces the transcription of iNOS. To understand the mechanism of induction
of iNOS, we investigated the role of NF-B and C/EBP␤,
transcription factors responsible for the induction of
iNOS. Activation of NF-B as well as C/EBP␤ by RSV-tat,
stimulation of RSV-tat-induced production of NO by the
wild type of p65 and C/EBP␤, and inhibition of RSV-tatinduced production of NO by ⌬p65, a dominant-negative
mutant of p65, and ⌬C/EBP␤, a dominant-negative mutant of C/EBP␤, suggest that RSV-tat induces iNOS
through the activation of NF-B and C/EBP␤. In addition, we show that extracellular signal-regulated kinase
(ERK) but not that p38 mitogen-activated protein kinase
(MAPK) is involved in RSV-tat induced production of
NO. Interestingly, PD98059, an inhibitor of the ERK
pathway, and ⌬ERK2, a dominant-negative mutant of
ERK2, inhibited RSV-tat-induced production of NO
through the inhibition of C/EBP␤ but not that of NF-B.
This study illustrates a novel role for HIV-1 tat in inducing the expression of iNOS in human astrocytes that
may participate in the pathogenesis of HIV-associated
dementia.

HIV-1 Tat Induces iNOS in Astroglia
tein, Tat, is a potent transactivator of viral and cellular gene
expression that is produced in the early phase of infection and
actively secreted into the extracellular environment, from
where it can act in an autocrine or a paracrine manner (18). We
report herein that the HIV-1 tat gene induces the production of
NO and the expression of iNOS through the activation of
NF-B and C/EBP␤ in human astrocytes.
MATERIALS AND METHODS

RNA Isolation and Northern Blot Analysis—Cells were taken out of
the culture dishes directly by adding Ultraspec-II RNA reagent (Biotecx
Laboratories, Inc.), and total RNA was isolated according to the manufacturer’s protocol. For Northern blot analyses, 20 g of total RNA was
electrophoresed on 1.2% denaturing formaldehyde-agarose gels, electrotransferred to Hybond nylon membrane (Amersham Biosciences),
and hybridized at 68 °C with 32P-labeled cDNA probe using Express
Hyb hybridization solution (Clontech) as described by the manufacturer. The cDNA probe was made by polymerase chain reaction amplification using two primers (forward primer, 5⬘-CTC CTT CAA AGA
GGC AAA AAT A-3⬘; reverse primer, 5⬘-CAC TTC CTC CAG GAT GTT
GT-3⬘) (26 –28). After hybridization, the filters were washed two or
three times in solution I (2⫻ SSC, 0.05% SDS) for 1 h at room temperature followed by solution II (0.1⫻ SSC, 0.1% SDS) at 50 °C for another
hour. The membranes were then dried and exposed to x-ray films
(Kodak). The same amount of RNA was hybridized with probe for
glyceraldehyde 3-phosphate dehydrogenase.
Assay of iNOS Promoter-derived Reporter Activity—Cells plated at
50 – 60% confluence in 6-well plates were cotransfected with 0.5 g of
phiNOS(7.2)Luc2 and different amounts of either RSV-tat or RSV-CAT
by LipofectAMINE Plus (Invitrogen) following the manufacturer’s protocol (22–24). All transfections also included 50 ng of pRL-TK (a plasmid encoding Renilla luciferase, used as transfection efficiency control;
Promega)/g of total DNA. Twenty-four hours after transfection, cells
were incubated with serum-free medium for 24 h. Firefly and Renilla
luciferase activities were obtained by analyzing total cell extract according to standard instructions provided in the Dual Luciferase Kit
(Promega) in a TD-20/20 luminometer (Turner Designs). Relative luciferase activity of cell extracts was typically represented as the ratio of
firefly luciferase value/Renilla luciferase value ⫻ 103.
Assay of Transcriptional Activities of NF-B and C/EBP␤—To assay
the transcriptional activities of NF-B and C/EBP␤, cells at 50 – 60%
confluence were transfected with either pBIIX-Luc, an NF-B-dependent reporter construct (31), or pC/EBP␤-Luc using the LipofectAMINE
Plus method (Invitrogen) (22–24). Construction of pC/EBP␤-Luc has
been described earlier (31). This C/EBP␤-sensitive promoter contains
four consensus C/EBP␤-binding sites. All transfections included 50
ng/g total DNA of pRL-TK (a plasmid encoding Renilla luciferase, used
as transfection efficiency control; Promega). After 24 h of transfection,
cells were treated with different stimuli for 6 h. Firefly and Renilla
luciferase activities were analyzed as described above.
Assay of ERK and p38 MAPK—U373MG astroglial cells (50 – 60%
confluent) were transfected with different concentrations of either RSVtat or RSV-CAT. Twenty-four hours after transfection, cells were incubated with serum-free medium. After 18 h of incubation, ERK and p38
MAPK activities were measured using assay kits obtained from Cell
Signaling Technology. Briefly, cells were harvested under nondenaturing conditions at different time intervals, and cell lysates were prepared. Activated forms of ERK and p38 MAPK were pulled down from
the cell lysate by immunoprecipitation using immobilized phospho-ERK
and phospho-p38 MAPK monoclonal antibodies, respectively. The pellets were washed twice with kinase buffer and finally resuspended with
50 l kinase buffer supplemented with 200 M ATP and either ELK-1
fusion protein (for ERK) or ATF-2 fusion protein (for p38 MAPK).
Following incubation at 30 °C for 30 min, samples were analyzed by
Western blot using antibodies against phospho-ELK-1 or
phospho-ATF-2.
RESULTS

Expression of RSV-tat but Not RSV-CAT Induces the Expression of iNOS in Human U373MG Astroglial Cells—To study
the effect of HIV-1 Tat on the expression of iNOS, we transfected human astroglial cells transiently with HIV-1 tat gene.
The plasmid RSV-tat expressing the exon I of the HIV-1 tat
gene under the control of the Rous sarcoma virus promoter was
used to transfect human U373MG astroglial cells. Expression
of RSV-tat but not of RSV-CAT induced the production of NO
(Table I). The inhibition of NO production by arginase, an
enzyme that degrades the substrate (L-arginine) of NOS, and
L-NMA, a competitive inhibitor of NOS, but not by D-NMA, a
negative control of L-NMA, suggests that RSV-tat induced the
production of NO in U373MG astroglial cells through NOS2
K. Pahan, X. Liu, B. S. Taylor, C. Wood, and S. M. Fischer, submitted for publication.
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Reagents—Fetal bovine serum, Hanks’ balanced salt solution, and
Dulbecco’s modified Eagle’s medium/F-12 were from Invitrogen. L-NGMonomethylarginine (L-NMA), D-NG-monomethylarginine (D-NMA),
PD98059, and SB203580 were purchased from Biomol. Arginase was
purchased from Sigma. Antibodies against mouse macrophage iNOS
were obtained from Calbiochem. Recombinant Tat protein and anti-Tat
monoclonal antibodies were obtained through the AIDS Research and
Reference Reagent Program, Division of AIDS, NIAID, National Institutes of Health. HIV-Tat was from Dr. J. Brady, Tat monoclonal antibodies from Dr. K. Krohn. 125I-labeled protein A, [␣-32P]dCTP, and
[␥-32P]ATP were obtained from PerkinElmer Life Sciences. Dominantnegative mutants of ERK1, ERK2, and p38 were kindly provided by
Dr. Jawed Alam (Alton Ochsner Medical Foundation, New Orleans,
LA). The wild type p65, the wild type C/EBP␤, and the dominantnegative mutant of C/EBP␤ were kindly provided by Dr. Sankar Ghosh
(Yale University School of Medicine), Dr. Ormond A. Macdougald (University of Michigan Medical School), and Dr. Steve Smale (University of
California at Los Angeles), respectively.
Preparation of Human Astrocytes—Human CNS tissue was obtained
from the Human Embryology Laboratory, University of Washington,
Seattle. The CNS tissue from each specimen was processed separately
and independently, as were subsequent cell cultures. There was no
pooling of CNS tissue from distinct specimens. All of the experimental
protocols were reviewed and approved by the Institutional Review
Board (IRB 224-01-FB) of the University of Nebraska Medical Center.
These cells were grown in a serum-free, defined medium (B16) enriched
with 5 ng of basic fibroblast growth factor/ml for optimal growth of
astrocytes and for the suppression of fibroblast growth (19). By immunofluorescence assay, these cultures homogeneously expressed glial
fibrillary acidic protein (GFAP). Cells were trypsinized, subcultured,
and stimulated with different cytokines in serum-free Dulbecco’s modified Eagle’s medium/F-12 medium.
Human U373MG astrocytoma cells obtained from American Type
Culture Collection (ATCC) were also maintained and induced with
different stimuli as indicated above.
Preparation of RSV-CAT and RSV-tat Constructs—The plasmid
RSV-CAT expressing the chloramphenicol acetyltransferase enzyme
under the control of the Rous sarcoma virus promoter was constructed
as described (20). The recombinant plasmid RSV-tat was constructed by
replacing the CAT gene in the RSV-CAT construct with the SalI-KpnI
fragment of HIV-1, which contains the exon I of the HIV tat gene. The
construction of this plasmid was described in detail previously (21).
Expression of RSV-CAT and RSV-tat in Human U373MG Astroglial
Cells and Primary Astrocytes—Cells at 50 – 60% confluence were transfected with different amounts of either RSV-CAT or RSV-tat construct
by LipofectAMINE Plus (Invitrogen) following the manufacturer’s protocol (22–24). Twenty-four hours after transfection, cells were incubated under serum-free conditions. After 24 h of incubation, culture
supernatants were transferred to measure NO production.
Assay for NO Synthesis—Synthesis of NO was determined by assay
of culture supernatants for nitrite, a stable reaction product of NO with
molecular oxygen. Briefly, 400 l of culture supernatant was allowed to
react with 200 l of Griess reagent (25–28) and incubated at room
temperature for 15 min. The optical density of the assay samples was
measured spectrophotometrically at 570 nm. Fresh culture medium
served as the blank in all experiments. Nitrite concentrations were
calculated from a standard curve derived from the reaction of NaNO2 in
the assay. Protein was measured by the procedure of Bradford (29).
Immunoblot Analysis for iNOS—Immunoblot analysis for iNOS was
carried out as described earlier (26 –28). Briefly, cells were detached by
scraping, washed with Hanks’ buffer, and homogenized in 50 mM TrisHCl (pH 7.4) containing protease inhibitors (1 mM phenylmethylsulfonyl fluoride, 5 g/ml aprotinin, 5 g/ml pepstatin A, and 5 g/ml
leupeptin). After electrophoresis the proteins were transferred onto a
nitrocellulose membrane, and the iNOS band was visualized by immunoblotting with antibodies against mouse macrophage iNOS and 125Ilabeled protein A.
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TABLE I
Expression of RSV-tat induces the production of NO in
human U373MG astroglial cells
Cells plated at 50 – 60% confluence in 6-well plates were transfected
with 0.2 g of either RSV-CAT or RSV-tat using LipofectAMINE Plus
(Invitrogen) as described under “Materials and Methods.” After 24 h of
transfection, cells were incubated under serum-free conditions in the
presence or absence of L-NMA (0.1 mM), D-NMA (0.1 mM), and arginase
(100 units/ml). After 24 h of incubation, the concentrations of nitrite
were measured in the supernatants as described under “Materials and
Methods.” Data are mean ⫾ S.D. of three different experiments.
Transfections and treatments

Nitrite

g/mg protein/24 h

RSV-CAT (0.2 g)
RSV-tat (0.2 g)
RSV-tat (0.2 g) ⫹ arginase
RSV-tat (0.2 g) ⫹ L-NMA
RSV-tat (0.2 g) ⫹ D-NMA

4.9 ⫾ 0.5
36.2 ⫾ 4.1
6.7 ⫾ 0.4
6.2 ⫾ 0.8
35.7 ⫾ 4.5

FIG. 1. Expression of RSV-tat induces the production of NO
and the expression of iNOS protein in human U373MG astroglial cells. Cells plated at 50 – 60% confluence in 6-well plates were
transfected with different amounts of either RSV-CAT or RSV-tat using
LipofectAMINE Plus (Invitrogen) as described under “Materials and
Methods.” After 24 h of transfection, cells were incubated under serumfree conditions. A, after 24 h of incubation, supernatants were used for
nitrite assay. Data are the mean ⫾ S.D. of three different experiments.
B, cell homogenates were electrophoresed, transferred onto nitrocellulose membrane, and immunoblotted with antibodies against mouse
macrophage iNOS as mentioned under “Materials and Methods.” C,
cells plated at 50 – 60% confluence in 100-mm dishes were transfected
with different amounts of either RSV-CAT or RSV-tat. After 24 h of
transfection, cells were incubated under serum-free conditions. After
24 h of incubation, cells were taken out directly by adding Ultraspec-II
RNA reagent (Biotecx Laboratories Inc.) to the plates for isolation of
total RNA, and Northern blot analysis for iNOS mRNA was carried out
as described under “Materials and Methods.”

tion of NO by about 4-fold (Fig. 2B). Taken together, these
observations suggest that the induction of iNOS in RSV-tattransfected astroglial cells is due to Tat and that Tat protein is
secreted from RSV-tat-transfected astroglial cells.
Expression of RSV-tat Induces the Production of NO in
Human Primary Astroglia—Human primary astrocytes have
been shown to induce the expression of iNOS in the presence of
different proinflammatory cytokines (23, 24).2 Because HIV-1
tat gene induced the production of NO in human U373MG
astroglial cells, we examined whether HIV-1 tat gene was also
able to induce the production of NO in human primary astrocytes (Fig. 3). Consistent with the induction of NO production
in human U373MG astroglial cells, expression of RSV-tat but
not RSV-CAT (the control plasmid) dose-dependently induced
the production of NO in human primary astroglia. The induction of NO was maximum at 0.2 g of RSV-tat and decreased at
higher concentration (Fig. 3).
RSV-tat Induces Human iNOS Promoter-derived Luciferase
Activity in Human U373MG Astroglial Cells—To understand
the effect of the tat gene on the transcription of iNOS, U373MG
glial cells were cotransfected with phiNOS(7.2)Luc, a construct
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mediated arginine metabolism (Table I). To study the dose
dependence of RSV-tat on the induction of NO production, cells
plated in 6-well plates were transfected with RSV-tat at different doses ranging from 0.05 to 0.5 g. The induction of NO
production started at 0.05 g of RSV-tat, reached the maximum at 0.2 g of RSV-tat, and decreased at higher doses (Fig.
1A). This decrease in NO production was due to the increase in
astroglial cell death when transfected at higher doses of RSVtat (data not shown). In contrast, cells transfected with different doses of RSV-CAT were unable to induce the production of
NO (Fig. 1A) suggesting that the induction of NO production is
due to the expression of the tat gene. To understand the mechanism of NO production, we examined the effect of RSV-tat and
RSV-CAT on protein and mRNA levels of iNOS. For Northern
blot analysis, cell plated in 100-mm dishes were transfected
with different doses of either RSV-CAT or RSV-tat (Fig. 1C).
Consistent with the induction of NO production, Western blot
analysis with antibodies against murine macrophage iNOS and
Northern blot analysis for iNOS mRNA clearly showed that
expression of RSV-CAT alone did not induce the expression of
iNOS protein and mRNA. However, marked expression of
iNOS protein (Fig. 1B) and mRNA (Fig. 1C) was observed in
cells transfected with different doses of RSV-tat. Similar to the
induction of NO production, the expression of iNOS protein and
mRNA by RSV-tat was also dose-dependent. The induction of
iNOS protein was maximal in cells transfected with 0.2 g (per
well of 6-well plate) of RSV-tat (Fig. 1B), whereas the expression of iNOS mRNA was maximal in cells transfected with 0.8
g (100-mm dish) of RSV-tat (Fig. 1C).
In the CNS, only microglia is known to be infected productively by HIV-1 and to secrete the HIV-1 regulatory protein,
Tat (2, 3, 32, 33) which in turn may act on astroglia in a
paracrine fashion (18). Therefore, to understand whether Tat
protein is secreted from RSV-tat-transfected astroglial cells
and whether Tat protein is in fact responsible for the induction
of iNOS, we incubated RSV-tat-transfected cells with anti-Tat
antibodies. Although anti-Tat antibodies at a dose of 1 g/ml
was not very effective in blocking the induction of NO production, about 50% inhibition of NO production was observed when
RSV-tat-transfected cells were incubated with 5 g/ml anti-Tat
antibodies (Fig. 2A). In contrast, control IgG had no effect on
the induction of NO production. We next examined whether
exogenously added recombinant HIV-1 Tat protein is able to
induce the production of NO. Consistent with the induction of
NO production by RSV-tat, recombinant Tat protein also dosedependently induced the production of NO with the maximum
induction observed at 100 ng/ml (Fig. 2B). However, in contrast
to the 8 –9-fold induction of NO production by the expression of
RSV-tat (Fig. 1A), recombinant Tat protein induced the produc-
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FIG. 2. Expression of RSV-tat induces the production of NO
through the secretion of tat in human U373MG astroglial cells.
A, cells plated in 6-well plates were transfected with 0.2 g of RSV-tat.
After 24 h of transfection, cells were incubated under serum-free conditions in the presence of different concentrations of anti-Tat antibodies
and control IgG. After 24 h of incubation, supernatants were used for
nitrite assay. Data are the mean ⫾ S.D. of three different experiments.
B, cells were treated with different concentrations of recombinant
HIV-1 Tat protein under serum-free conditions. After 24 h, supernatants were used for nitrite assay. Data are the mean ⫾ S.D. of three
different experiments.

FIG. 3. Expression of RSV-tat induces the production of NO in
human primary astroglia. Cells plated at 50 – 60% confluence in
6-well plates were transfected with different amounts of either RSVCAT or RSV-tat. After 24 h of transfection, cells were incubated under
serum-free conditions. After 24 h of incubation, supernatants were used
for nitrite assay. Data are the mean ⫾ S.D. of three different
experiments.

containing the human iNOS promoter fused to the luciferase
gene,2 and either RSV-tat or RSV-CAT. Activation of the iNOS
promoter was measured after incubating the cells with serumfree media. It is evident from Fig. 4 that transfection of cells

with different amounts of RSV-tat but not RSV-CAT led to the
induction of iNOS promoter-derived luciferase activity. About
3.7-fold activation of iNOS promoter-derived luciferase activity
was observed in cells transfected with 0.2 g of RSV-tat (Fig.
4). These results suggest that the induction rate of the human
iNOS promoter construct is much lower than the induction rate
of human iNOS mRNA expression (Fig. 1C). We used a 7.2-kb
human iNOS promoter for this study. Earlier, Taylor et al. (34)
showed a 4.1-fold induction of this human iNOS promoter in
human AKN-1 liver cells. They have also shown that transfection of a 16-kb human iNOS promoter construct produced a
9-fold increase in luciferase activity following cytokine stimulation, suggesting that there are additional functional elements
even further upstream from 7.2 kb. Consistently, Marks-Konczalik et al. (35) have also shown the presence of extra NF-Band AP-1-binding sites within 7.2– 8.3-kb human iNOS promoter, which is responsible for higher promoter activity in
response to cytokines. Therefore, the observed low induction of
7.2-kb human iNOS promoter by RSV-tat in human U373MG
astroglial cells is probably due to the absence of extra NF-Band AP-1-binding sites.
Role of NF-B and C/EBP␤ in RSV-tat-mediated Induction of
iNOS in U373MG Astroglial Cells—The presence of NF-B
DNA-binding sites in the promoter of iNOS (34 –36) and the
inhibition of expression of iNOS by the inhibitors of NF-B
suggests that NF-B plays an important role in the expression
of iNOS (22–24, 26 –28, 31, 36). Recent studies also have shown
that activation of C/EBP␤ is important for the induction of
mouse as well as human iNOS (31).2 These findings prompted
us to ask whether activation of NF-B and C/EBP␤ may be
responsible for the induction of iNOS following HIV-1 tat gene
expression in U373MG astroglial cells. First, we considered
whether these two transcription factors are activated by RSVtat. Activation of these transcription factors was monitored by
transcriptional activities using the expression of luciferase
from reporter constructs like pBIIX-Luc (for NF-B) and pC/
EBP␤-Luc (for C/EBP␤) as an assay. Expression of RSV-tat but
not RSV-CAT induced the activation of both NF-B (Fig. 5A)
and C/EBP␤ (Fig. 5B) in a dose-dependent fashion. The maxi-
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FIG. 4. Expression of RSV-tat induces iNOS promoter-derived
luciferase activity in human U373MG astroglial cells. Cells plated
in 6-well plates were cotransfected with 0.5 g of phiNOS(7.2)Luc (a
construct containing the human iNOS promoter fused to the luciferase
gene) and different amounts of either RSV-CAT or RSV-tat. All transfections also included 50 ng/g pRL-TK (as transfection efficiency control). After 24 h of transfection, cells were incubated under serum-free
conditions for 18 h. Firefly (ff-Luc) and Renilla (r-Luc) luciferase activities were obtained by analyzing total cell extract as described under
“Materials and Methods.” Data are the mean ⫾ S.D. of three different
experiments.
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mum activation (⬃9 –12-fold) of these transcription factors occurred in cells transfected with 0.2 g of RSV-tat.
Next we examined whether activation of both NF-B and
C/EBP␤ is important for RSV-tat-induced production of NO.
Overexpression of dominant-negative molecules provides an
effective tool with which to investigate the in vivo functions of
different transcription factors and signaling molecules. NF-B
was inhibited by a dominant-negative mutant of p65 (⌬p65)
(31). A naturally occurring alternate C/EBP␤ translation product, known as LIP, lacks an “activation domain” and yet retains
the ability to inhibit the function of C/EBP␤ (37). LIP therefore
acts as a dominant-negative mutant of C/EBP␤ (37). Expression of ⌬p65 as well as ⌬C/EBP␤, but not the empty vector,
inhibited the production of NO (Fig. 6) in RSV-tat-transfected
cells. In contrast, expression of wild type p65 and C/EBP␤
stimulated RSV-tat-induced production of NO (Fig. 6). These
studies suggest that activation of both NF-B and C/EBP␤ is
important for RSV-tat-induced production of NO in human
astroglial cells.
Role of ERK and p38 MAPK in RSV-tat-induced Production
of NO in Human U373MG Astroglial Cells—In eukaryotic cells,
an important group of signaling pathways is the mitogen-activated protein kinase (MAPK) signaling cascades (38). Because
the activation of MAPK pathways such as ERK and p38 MAPK
by lipopolysaccharide and cytokines represents a potential signaling mechanism for NO production during the inflammatory
response (27, 39, 40), we investigated the role of ERK and p38
MAPK in RSV-tat-induced production of NO. Therefore, we
first examined the effect of RSV-tat on the activation of these
kinases in U373MG astroglial cells. Interestingly, expression of
RSV-tat induced the activation of ERK (Fig. 7). Consistent with
the effect of RSV-tat on the induction of NO production and the
activation of NF-B and C/EBP␤, there was an inhibition of
ERK activation in cells transfected with higher amount (0.5 or
1.0 g) of RSV-tat (Fig. 7). In contrast, under the same conditions, the activation of p38 MAPK was not detected, suggesting

FIG. 7. Expression of RSV-tat induces activation of ERK in
human U373MG astroglial cells. Cells were transfected with different amounts of RSV-tat. After 24 h of transfection, cells were incubated
under serum-free conditions. After 18 h of incubation, activities of ERK
and p38 MAPK were assayed as described under “Materials and
Methods.”

that ERK but not p38 MAPK may play an important role in
RSV-tat-induced production of NO in human astroglial cells.
Therefore, we investigated the role of ERK and p38 MAPK in
RSV-tat-induced production of NO using specific pharmacological inhibitors of MEK-ERK (PD98059) and p38 MAPK
(SB203580). Twenty-four hours after transfection with 0.2 g
of RSV-tat, cells were incubated with different concentrations
of PD98059 or SB203580 under serum-free conditions. After
24 h of incubation, the concentration of nitrite was measured in
supernatants. Both PD98059 and SB203580 were dissolved in
Me2SO. These drugs were added to the cell culture at a final
Me2SO concentration of 0.02– 0.06%. Me2SO (0.06%) was used
as a control. Consistent with the activation of ERK but not p38
MAPK by RSV-tat, PD98059 but not SB203580 dose-dependently inhibited the production of NO in RSV-tat-transfected
cells (Fig. 8A), suggesting that ERK but not p38 MAPK is
involved in RSV-tat-induced production of NO. The inhibition
by PD98059 was not from Me2SO because Me2SO alone did not
exhibit any inhibitory effect at the highest concentration used
in our study (data not shown). To further confirm the involvement of ERK but not p38 MAPK in RSV-tat-induced production
of NO, we studied the effect of dominant-negative mutants of
ERK1 (⌬ERK1), ERK2 (⌬ERK2), and p38 (⌬p38) on RSV-tatinduced production of NO. Interestingly, RSV-tat-induced production of NO was inhibited by ⌬ERK2 but not by ⌬ERK1,
suggesting that ERK2 but not ERK1 is involved in RSV-tatinduced production of NO (Fig. 8B). In addition, consistent with
the inability of RSV-tat to induce the activation of p38 MAPK
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FIG. 5. Expression of RSV-tat induces activation of NF-B and
C/EBP␤ in human U373MG astroglial cells. Cells plated in 6-well
plates were cotransfected with 0.5 g of either pBIIX-Luc (A) or pC/
EBP␤-Luc (B) and different amounts of either RSV-CAT or RSV-tat. All
transfections also included 50 ng/g pRL-TK. After 24 h of transfection,
cells were incubated under serum-free conditions for 18 h. Firefly (ffLuc) and Renilla (r-Luc) luciferase activities were obtained by analyzing total cell extract. Data are the mean ⫾ S.D. of three different
experiments.

FIG. 6. Effect of wild-type p65 and C/EBP␤ and dominant-negative mutants of p65 (⌬p65) and C/EBP␤ (⌬C/EBP␤) on RSV-tatinduced production of NO in human U373MG astroglial cells.
Cells plated in 6-well plates were cotransfected with 0.2 g of RSV-tat
and 0.5 g of an empty vector, p65, C/EBP␤, ⌬p65, or ⌬C/EBP␤. After
24 h of transfection, cells were incubated under serum-free conditions
for another 24 h. Supernatants were used for the nitrite assay. Data are
the mean ⫾ S.D. of three different experiments.
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FIG. 8. Role of ERK and p38 MAPK in RSV-tat-induced NO
production in human U373MG astroglial cells. A, cells were transfected with 0.2 g of RSV-tat. After 24 h of transfection, cells were
incubated under serum-free conditions in the presence or absence of
different concentrations of PD98059 and SB203580. After 24 h of incubation, supernatants were used for the nitrite assay. Data are the
mean ⫾ S.D. of three different experiments. B, cells were cotransfected
with 0.2 g of RSV-tat and 0.5 g of either an empty vector or ⌬ERK1,
⌬ERK2, or ⌬p38. After 24 h of transfection, cells were incubated under
serum-free conditions for another 24 h. Supernatants were used for the
nitrite assay. Data are the mean ⫾ S.D. of three different experiments.

and the inability of SB203580 to inhibit RSV-tat-induced production of NO, ⌬p38 had no effect on RSV-tat-induced production of NO (Fig. 8B).
Is ERK2 Involved in RSV-tat-induced Activation of NF-B
and C/EBP␤ in Human U373MG Astroglial Cells?—The results presented in Fig. 8 show that RSV-tat induces the production of NO through ERK2. Because proinflammatory transcription factors NF-B and C/EBP␤ are also involved in
RSV-tat-induced production of NO, we next examined the effect
of PD98059 and ⌬ERK2 on RSV-tat-induced activation of
NF-B and C/EBP␤. Interestingly, PD98059 at different tested
doses had no inhibitory effect on RSV-tat-induced activation of
NF-B (Fig. 9A). Even PD98059 at a dose of 25 M stimulated
RSV-tat-induced activation of NF-B (Fig. 9A). In sharp contrast, PD98059 dose-dependently inhibited RSV-tat-induced
activation of C/EBP␤ (Fig. 9B). Because PD98059 inhibits the
MEK-ERK pathway, these results suggest that ERK2 is probably involved in RSV-tat-induced activation of C/EBP␤ but not
of NF-B. To further confirm this observation, we tested the
effect of ⌬ERK2 on RSV-tat-induced activation of NF-B and
C/EBP␤. Consistent with the effect of PD98059 on RSV-tat-

induced activation of NF-B and C/EBP␤, ⌬ERK2 specifically
inhibited the activation of C/EBP␤ (Fig. 10B) but not of NF-B
(Fig. 10A). These experiments suggest that PD98059 and
⌬ERK2 inhibit RSV-tat-induced production of NO by inhibiting
the activation of C/EBP␤ but not NF-B.
DISCUSSION

The pathogenesis of dementia associated with HIV-1 infection involves the complex interactions between viral products
and host immune system, which eventually result in neuronal
dysfunction and cell loss. Several findings suggest that extracellular Tat plays an important role in the pathogenesis of
HAD. First, Tat is actively secreted by infected cells of HAD
patients (32, 33). Second, anti-Tat antibodies are frequently
detected in the serum of HAD patients (41). Third, Tat mRNA
is elevated in patients with HAD (42, 43). Fourth, a single
intraventricular injection of Tat leads to macrophage infiltration, progressive glial activation, and neuronal death, pathologies that are also observed in HAD brains (44). However, the
mechanism by which Tat causes neuronal death in HAD patients is poorly understood. Astroglia are the major glial cells in
the CNS, and reactive astroglia have been found in large numbers in the brains of HAD patients. The evidence presented in
this manuscript that RSV-tat but not RSV-CAT (the control
plasmid) induced the production of NO and the expression of
iNOS, that anti-Tat antibodies blocked RSV-tat-induced production of NO, and that recombinant Tat protein also induced
the production of NO clearly support the conclusion that Tat
induces the expression of iNOS in human astrocytes. The ability of Tat to induce the production of NO in humanU373MG
astroglial cells and primary astroglia suggests that neurons in
the vicinity of Tat-activated astroglia in brains of HAD patients
could be subjected to NO-induced damage.
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FIG. 9. Effect of PD98059 on RSV-tat-induced activation of
NF-B and C/EBP␤ in human U373MG astroglial cells. Cells
plated in 6-well plates were cotransfected with 0.2 g of RSV-tat and 0.5
g of either pBIIX-Luc (A) or pC/EBP␤-Luc (B). All transfections also
included 50 ng/g pRL-TK. After 24 h of transfection, cells were incubated in the presence or absence of different concentrations of PD98059
under serum-free conditions for 18 h. Firefly (ff-Luc) and Renilla (r-Luc)
luciferase activities were obtained by analyzing total cell extract. Data
are the mean ⫾ S.D. of three different experiments.
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In vitro iNOS has been shown to be induced in glial cells
following exposure to HIV-1 or HIV-1 envelope glycoproteins
such as gp120 and gp41 (45– 47). Although earlier studies reported iNOS expression in monocyte-derived macrophages, microglia, and astrocytes (45– 46), more recent studies have demonstrated an inability of macrophages or microglia to express
iNOS following stimulation with HIV or gp41 (47) at least in
vitro. Particularly, gp41 has been shown to induce iNOS in
astrocytes but not in the absence of monocyte-derived macrophages (14). Recently Polazzi et al. (48) reported that HIV-1 Tat
protein induces the production of NO in mouse microglial cells.
However, immunocytochemical analysis of HAD brains has
shown that iNOS is primarily expressed in astrocytes (15). In
contrast, the majority of macrophages or microglia (including
multinucleated giant cells) remain iNOS-negative (15). In light
of these findings, our observations suggest that Tat may also
contribute to the expression of iNOS observed in astroglia of
HAD brains. However, Barton et al. (49) have reported that
HIV-1 Tat inhibits interferon-␥-induced iNOS activity in murine macrophages. There are several instances in which the
induction of iNOS is differentially regulated in astrocytes and
macrophages. First, increasing cAMP or protein kinase A inhibits iNOS in astrocytes (26, 50) but stimulates iNOS macrophages (26). Second, inhibitors of protein phosphatase 1/2A
stimulate iNOS in astrocytes (51) but inhibit iNOS in macrophages (51, 52). Third, ceramide stimulates iNOS in astrocytes
(26) but inhibits iNOS in macrophages (53). Therefore, Tat may
regulate the expression of iNOS differentially in astrocytes and
macrophages.
The signaling events in the induction of iNOS have not been
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FIG. 10. Effect of ⌬ERK2, the dominant-negative mutant of
ERK2, on RSV-tat-induced activation of NF-B and C/EBP␤ in
human U373MG astroglial cells. Cells were cotransfected with 0.2
g of RSV-tat, 0.5 g of either an empty vector or ⌬ERK2, and 0.5 g of
either pBIIX-Luc (A) or pC/EBP␤-Luc (B). After 24 h of transfection,
cells were incubated under serum-free conditions for 18 h. Firefly (ffLuc) and Renilla (r-Luc) luciferase activities were obtained by analyzing total cell extract. Data are the mean ⫾ S.D. of three different
experiments.

completely established so far. Proinflammatory cytokines (tumor necrosis factor-␣, interleukin-1␤, or interferon-␥) and lipopolysaccharide bind to their respective receptors and induce
the expression of iNOS via NF-B activation (22–24, 26 –28, 31,
36). The presence of a consensus sequence in the promoter
region of iNOS for the binding of NF-B (34 –36) and the
inhibition of iNOS expression with the inhibition of NF-B
activation establish an essential role for NF-B activation in
the induction of iNOS. Activation of NF-B by various cellular
stimuli involves the proteolytic degradation of IB, the inhibitory subunit of the NF-B complex, and the concomitant nuclear translocation of the liberated NF-B heterodimer. Although the biochemical mechanism underlying the degradation
of IB remains unclear, it appears that degradation of IB
induced by various mitogens and cytokines occurs in association with the transient phosphorylation of IB on serines 32
and 36. Consistently, two closely related kinases (IKK␣ and
IKK␤) that directly phosphorylate IB␣ have also been described (reviewed in Ref. 54). Upon phosphorylation, IB that is
still bound to NF-B apparently becomes a high affinity substrate for an ubiquitin-conjugating enzyme. After phosphorylation-dependent ubiquitination, the IB is rapidly and completely degraded by the 20 or 26 S proteasome, the NF-B
heterodimer enters into the nucleus (reviewed in Ref. 54) and
binds to the consensus DNA-binding site present in the promoter region of iNOS. Our results have shown clearly that the
activation of NF-B is important for the expression of iNOS in
RSV-tat-transfected astrocytes. First, RSV-tat but not RSVCAT induced the activation of NF-B. Second, ⌬p65, a dominant-negative mutant of p65, but not the empty vector inhibited RSV-tat-induced production of NO. Third, overexpression
of the wild type p65 stimulated RSV-tat-induced production
of NO.
CCAAT/enhancer-binding protein (C/EBP) is a member of
the basic region-leucine zipper family of transcription factors
that controls the transcription of a number of genes through
protein-protein interactions at the gene level (37). In particular, C/EBP␤ not only can bind to its own family members such
as C/EBP proteins, Fos, and Jun (55), but also forms complexes
with other transcription factors such as NF-B, estrogen receptor, and an Sp1 factor (56). In addition, C/EBP␤ may also alter
transcription by complex interactions with coactivators and
basal transcription factors such as TFIIB and p300 (57). The
8.3-kb human iNOS promoter contains 15 nucleotide sequences
(58) that conform to the consensus C/EBP box TKNNGYAAK
(37). Recently we have found that the dominant-negative mutant of C/EBP␤ inhibits cytokine-induced production of NO in
human astroglial cells2 suggesting the involvement of C/EBP␤
in cytokine-induced expression of iNOS. The results presented
in this article clearly demonstrate that the activation of
C/EBP␤ is also essential for RSV-tat-mediated induction of
iNOS in human astrocytes. First, RSV-tat induced the activation of C/EBP␤. Second, ⌬C/EBP␤, a truncated alternate
C/EBP␤ translation product, LIP, which acts as a dominantnegative inhibitor of C/EBP␤ activity (37), inhibited RSV-tatinduced production of NO. Third, overexpression of wild type
C/EBP␤ stimulated RSV-tat-induced production of NO.
At present, it is unclear how Tat activates NF-B and
C/EBP␤ to induce the production of NO in astroglial cells.
MAPKs are Ser-Thr kinases that have been shown to activate
a number of transcription factors in different cell types in
response to various stimuli (38). We have found that the expression of RSV-tat induces the activation of ERK only and not
p38 MAPK. Consistently, using pharmacological inhibitors and
dominant-negative mutants, we have elucidated that ERK but
not p38 MAPK is involved in RSV-tat-induced production of
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NO. There are two isoforms of ERK (ERK1 and ERK2) (38).
Interestingly, ERK2 but not ERK1 is involved in RSV-tatinduced production of NO in human astroglial cells. In addition, RSV-tat-induced ERK2 couples with C/EBP␤ only and not
with NF-B. Taken together, our studies suggest that Tat
activates ERK2, which ultimately couples to the activation of
C/EBP␤ but not to NF-B for the induction of iNOS. Further
studies are under way to delineate the Tat-induced signaling
pathway(s) that couples with NF-B for the induction of iNOS.
NO, a diffusible free radical, plays many roles as a signaling
and an effector molecule in diverse biological systems, including neurotransmission, vasodilation, and antimicrobial and antitumor activities (10, 11). In the nervous system small
amounts of NO produced by neuronal NO synthase act as a
neurotransmitter. In sharp contrast, excessive amounts of NO
produced from the activation of iNOS is directly or indirectly
neurotoxic via stimulation of N-methyl-D-aspartate receptors,
leading to necrosis and apoptosis (59). In addition, NO and
peroxynitrite (reaction product of NO and O2⫺) may mediate
toxicity in neurons and oligodendrocytes through the formation
of iron-NO complexes of iron-containing enzyme systems, oxidation of protein sulfhydryl groups, nitration of proteins, and
nitrosylation of nucleic acids and DNA strand breaks (11). NO
can also modulate macrophage apoptosis, lymphocyte proliferation, and chemokine induction (11, 60, 61) and thus could
regulate the overall inflammatory responses in the CNS. iNOS
expressed in astrocytes could contribute to the breach of the
blood-brain barrier due to its potent vasorelaxing property,
allowing extravasation of the harmful molecules to the CNS.
Such an abnormality in the blood-brain barrier could contribute to the diffuse myelin damage that is often associated with
HAD (62). On the other hand, NO also exhibits antiviral activity against a wide range of viruses in rodents (e.g. herpes
simplex, vaccinia, ectromelia, vesicular stomatitis, Friend leukemia, coxsackievirus, Japanese encephalitis viruses, and coronavirus) (reviewed in Ref. 10). Therefore, the existence of NOmediated antiviral activity against HIV-1 is probably
responsible for the observed low levels of virus detectable in
vivo even in the presence of significant neurologic damage.
In the CNS, iNOS is expressed mainly by activated astroglia
and microglia, the two glial cell types involved in intracerebral
immune regulation. Astroglia are the major glial cell population in the CNS, and therefore, induction of iNOS in astroglia
by Tat may be an important source of NO in HAD associated
with astrogliosis and neuronal death.
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